Legal Notices
© 2002-2011 Prometheus. All Rights Reserved
Terms & Conditions
Terms of Use of this Web Site
The following terms apply to all visitors or users of the Web site. By accessing this Web site, you acknowledge acceptance of these terms. Prometheus reserves the right to change these terms from time to time at its sole discretion. In the case of any violation of these terms, Prometheus reserves the right to seek all remedies available by law and in equity for such violations. These terms apply to all visits to the Prometheus Web site, both now and in the future.
Disclaimer and Limitation of Liability
This Web site is provided as a service to its visitors for informational purposes and for your general interest and entertainment only. By using this Web site you hereby agree not to rely on any of the information contained herein. This Web site is not designed to provide a diagnosis or medical advice and should not be relied on or interpreted as doing so. Any information in this Web site relating to various health and medical conditions is provided for information purposes only. It is not meant to be a substitute for the advice provided by a physician or other healthcare professional. You should always consult a physician or healthcare provider for your personal medical needs. Prometheus will use reasonable efforts to include accurate and up-to-date information on this Web site. The materials at this site may be out of date by the time that they may be accessed or read. Some materials presented could include technical inaccuracies or typographical errors. Prometheus reserves the right to make changes or improvements to this Web site at any time. THE MATERIALS ON THIS WEB SITE ARE PROVIDED "AS IS" AND WITHOUT WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED. TO THE FULLEST EXTENT PERMISSIBLE PURSUANT TO APPLICABLE LAW, PROMETHEUS DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF INTELLECTUAL PROPERTY. INFORMATION ON THIS WEB SITE MAY REFER TO PRODUCTS, PROGRAMS, OR SERVICES THAT ARE NOT AVAILABLE IN YOUR COUNTRY.
IN NO EVENT WILL PROMETHEUS OR THIRD PARTIES MENTIONED AT THIS SITE BE LIABLE FOR ANY DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, THOSE RESULTING FROM LOST PROFITS, LOST DATA, OR BUSINESS INTERRUPTION) ARISING OUT OF THE USE, INABILITY TO USE, OR THE RESULTS OF USE OF THIS SITE, ANY WEB SITES LINKED TO THIS SITE, OR THE MATERIALS OR INFORMATION CONTAINED AT ANY OR ALL SUCH SITES, WHETHER BASED ON WARRANTY, CONTRACT, TORT, OR ANY OTHER LEGAL THEORY AND WHETHER OR NOT ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IF YOUR USE OF THIS SITE RESULTS IN THE NEED FOR SERVICING, REPAIR, OR CORRECTION OF EQUIPMENT OR DATA, YOU ASSUME ALL COSTS THEREOF. APPLICABLE LAW MAY NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU.
Forward-Looking Statements
Except for historical information, this Web site contains forward-looking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made, including the Company's dependence on sales of key products, uncertainty of future financial results and fluctuations in operating results, dependence on the Company's acquisition strategy, new product introductions, and other risks from time to time. These forward-looking statements represent the judgment of the Company as of the date of this Web site development and/or update, and Prometheus disclaims any intent or obligation to update these forward–looking statements.
Patents
Prometheus spends millions of dollars each year in discovery, development, acquisition and protection of its diagnostic and therapeutic products. Much of the Company's technology is protected by U.S. and foreign patents. A patent provides protection for the Company's exclusive use and development of certain product technology and methodologies for a specific period of time.
Prometheus products, services, and technology may be covered by one or more U.S. pending or issued patents. Details of the patent coverage may be found at http://www.prometheuslabs.com/Legal.asp.
In addition, foreign patents may be issued or pending on the Company's products, technologies and services.
Trademarks
All logos, trademarks, and service marks (the "Trademarks") displayed on this site whether or not appearing in large print or with or without the trademark symbol are registered and unregistered Trademarks of Prometheus Laboratories Inc. or of respective third parties . Your access to this Web site should not be construed as granting, by implication, estoppel or otherwise, any license or right to use any marks appearing on the Web site without the prior written consent of Prometheus or the third-party owner there of.
Copyright
The content of this Web site is protected by applicable copyright, trademark and other intellectual property laws. All material published in this Web site (including but not limited to images, illustrations, information, documents and related graphics) is the sole property of Prometheus and may not be reproduced, modified, uploaded, downloaded, posted, transmitted, republished or distributed without Prometheus' written permission. Modification of the content or use of the content for any other purpose is a violation of the copyrights and other proprietary rights of Prometheus. Prometheus hereby authorizes you to copy certain materials published by Prometheus on this Web site and identified as "Resources" solely for non-commercial use within your organization. No other use of the information is authorized. In consideration of this authorization, you agree that any copy of these materials will retain all copyright and other proprietary notices in the same form and manner as on the original. Except as specified above, nothing contained herein will be construed as conferring by implication, estoppel, or otherwise, any license or right under any intellectual property rights of Prometheus or any third party.
Applicable Laws
This Web site is controlled by Prometheus from its offices in San Diego, California. Prometheus makes no representation that the information on the Web site is appropriate or available for use outside the United States, and access to it from territories where its contents is illegal is prohibited. If you chose to access this Web site from outside the United States, you do so on your own initiative and are responsible for compliance with applicable local laws. You may not use or export the information contained in this Web site in violation of U.S. export laws and regulations. Your access to this Web site is governed by all applicable federal, state, and local laws and may also be subject to the laws of the country where you reside.
Links to Others
Links to third-party Web sites on this site are provided solely as a convenience to you. If you use these links, you are leaving this Web site. Prometheus has not reviewed all of these third-party sites and does not control and is not responsible for any of their content. Furthermore, Prometheus does not endorse or make any representations about them, or any information, software or other products or materials found there, or any results that may be obtained from using them. If you access any of the third-party sites linked to this Web site, you do this entirely at your own risk and expressly release Prometheus, and its subsidiaries, officers, directors and employees from any and all consequences, damages, and liabilities resulting there from.
Personal Information
In some circumstances, Prometheus may request personal information from you, such as your name, E-mail address, company name, or telephone number. Your response to these inquiries is strictly voluntary. The information we collect is used to improve the content of our Web site and may be used to contact you, via E-mail or regular mail, to provide you with information we believe may be of interest to you. We do not share this information with other organizations for commercial purposes. Information that is not personal or is not associated with any personally identifiable data, such as questions, comments, ideas, and suggestions, shall be deemed to be non-confidential, and Prometheus shall be free to disclose and use the same for any purpose, without any obligation whatsoever to you.
Domain Information
Prometheus also collects domain information as part of its analysis of the use of this site. The data enables us to become more familiar with customers that visit our site, such as how often they visit and what parts of the site they visit most often. This information is used to improve our Web site.
Use of "Cookies"
Cookies are small files that many Web sites place on your hard drive that allow those Web sites to identify you. The use of cookies is a standard and common practice of many Web sites. For example, if you allow a web site to remember your login name or password, the web site places a cookie on your computer. We may place cookies on your computer to allow us to identify you during future visits to our Web site. We may use cookies to measure web traffic, to offer you certain products or services, and to customize your visit. However, if you do not wish to receive cookies, or want to be notified of when they are placed, your internet browser may permit you to do so. In many internet browsers, you can change the browser settings to warn you before accepting cookies or to block cookies. If you block cookies, you may not be able to use certain Web site features or functions, or this Web site may not operate in an optimal mode.
Privacy Protections for Minors
Prometheus' web site is not directed at or intended for minors. Therefore, we do not wish to receive, nor do we knowingly collect, personal information from minors via this Web site.
Summary of Important Safety Information for Proleukin® (aldesleukin) for injection, for intravenous infusion
WARNINGS
Therapy with Proleukin® (aldesleukin) should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.
Proleukin should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.
Proleukin administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.
Proleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of Proleukin therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.
Proleukin administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.
INDICATION AND USAGE
Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC).
Proleukin is indicated for the treatment of adults with metastatic melanoma.
Careful patient selection is mandatory prior to the administration of Proleukin.
Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity. Therefore, selection of patients for treatment should include assessment of performance status.
Experience in patients with ECOG PS >1 is extremely limited.
CONTRAINDICATIONS
Proleukin® (aldesleukin) is contraindicated in patients with a known history of hypersensitivity to interleukin-2 or any component of the Proleukin formulation.
Proleukin is contraindicated in patients with an abnormal thallium stress test or abnormal pulmonary function tests and those with organ allografts. Retreatment with Proleukin is contraindicated in patients who have experienced the following drug-related toxicities while receiving an earlier course of therapy: Sustained ventricular tachycardia (≥5 beats), Cardiac arrhythmias not controlled or unresponsive to management, Chest pain with ECG changes, consistent with angina or myocardial infarction, Cardiac tamponade, Intubation for >72 hours, Renal failure requiring dialysis >72 hours, Coma or toxic psychosis lasting >48 hours, Repetitive or difficult to control seizures, Bowel ischemia/perforation, GI bleeding requiring surgery.
WARNINGS
Because of the severe adverse events which generally accompany Proleukin® (aldesleukin) therapy at the recommended dosages, thorough clinical evaluation should be performed to identify patients with significant cardiac, pulmonary, renal, hepatic, or CNS impairment in whom Proleukin is contraindicated. Patients with normal cardiovascular, pulmonary, hepatic, and CNS function may experience serious, life threatening or fatal adverse events. Adverse events are frequent, often serious, and sometimes fatal.
Should adverse events, requiring dose modification occur, dosage should be withheld rather than reduced.
Proleukin has been associated with exacerbation of pre-existing autoimmune disease and inflammatory disorders. In some cases, the onset of new autoimmune diseases, such as vitiligo, may occur. Symptomatic hyperglycemia and/or diabetes mellitus have been reported during Proleukin therapy.
All patients should have thorough evaluation and treatment of CNS metastases and have a negative scan prior to receiving Proleukin therapy. New neurologic signs, symptoms, and anatomic lesions following Proleukin therapy have been reported in patients without evidence of CNS metastases. Neurologic signs and symptoms associated with Proleukin therapy usually improve after discontinuation of Proleukin therapy; however, there are reports of permanent neurologic defects. In patients with known seizure disorders, extreme caution should be exercised as Proleukin may cause seizures.
PRECAUTIONS
Patients should have normal cardiac, pulmonary, hepatic, and CNS function at the start of therapy. Capillary leak syndrome (CLS) begins immediately after Proleukin® (aldesleukin) treatment starts and is marked by increased capillary permeability to protein and fluids and reduced vascular tone.
Proleukin® (aldesleukin) treatment should be withheld for failure to maintain organ perfusion as demonstrated by altered mental status, reduced urine output, a fall in the systolic blood pressure below 90 mm Hg or onset of cardiac arrhythmias.
Recovery from CLS begins soon after cessation of Proleukin therapy. Usually, within a few hours, the blood pressure rises, organ perfusion is restored and reabsorption of extravasated fluid and protein begins.
Kidney and liver function are impaired during Proleukin treatment. Use of concomitant nephrotoxic or hepatotoxic medications may further increase toxicity to the kidney or liver.
Mental status changes including irritability, confusion, or depression which occur while receiving Proleukin may be due to bacteremia or early bacterial sepsis, hypoperfusion, occult CNS malignancy, or direct Proleukin-induced CNS toxicity. Patients should be evaluated for these and other causes of mental status changes. Alterations in mental status due solely to Proleukin therapy may progress for several days before recovery begins. Rarely, patients have sustained permanent neurologic deficits.
Proleukin enhancement of cellular immune function may increase the risk of allograft rejection in transplant patients.
Serious manifestations of eosinophilia involving eosinophilic infiltration of cardiac and pulmonary tissues can occur following Proleukin.
ADVERSE REACTIONS
The rate of drug-related deaths in the 255 metastatic RCC patients who received single-agent Proleukin® (aldesleukin) was 4% (11/255); the rate of drug-related deaths in the 270 metastatic melanoma patients who received single-agent PROLEUKIN was 2% (6/270).
In clinical trials, the following life-threatening (Grade 4) adverse events were seen in >1% of 525 patients (255 with metastatic renal cell cancer and 270 with metastatic melanoma) treated with PROLEUKIN: oliguria (6%), anuria (5%), hypotension (3%), respiratory disorder (3%), bilirubinemia (2%), coma (2%), diarrhea (2%), acidosis (1%), acute kidney failure (1%), apnea (1%), cardiovascular disorder (1%), coagulation disorders (1%), confusion (1%), creatinine increase (1%), dyspnea (1%), fever (1%), heart arrest (1%), infection (1%), myocardial infarct (1%), psychosis (1%), sepsis (1%), SGOT increase (1%), stupor (1%), supraventricular tachycardia (1%), thrombocytopenia (1%), ventricular tachycardia (1%), and vomiting (1%). From the same trials, the following adverse events (Grades 1-4) were seen in ≥30% of 525 patients (255 with metastatic renal cell cancer and 270 with metastatic melanoma) treated with PROLEUKIN: hypotension (71%), diarrhea (67%), oliguria (63%), chills (52%), vomiting (50%), dyspnea (43%), rash (42%), bilirubinemia (40%), thrombocytopenia (37%), nausea (35%), confusion (34%), and creatinine increase (33%).
Please see the full Prescribing Information, including Boxed Warning, for Proleukin® (aldesleukin) for injection, for intravenous infusion.
The content contained in this website is not intended to be a substitute for professional medical advice related to any topic discussed. Patients are urged to consult with their treating physicians or other professionals. Never disregard professional, medical, or legal advice or delay seeking such advice because of something you have read on this website.